WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 571193
Description: A 70450 is an inhibitor of aspartyl proteinase. It can be used as an antifungal agent and may have a role in HIV protease inhibition therapy.
MedKoo Cat#: 571193
Name: A 70450
Chemical Formula: C19H39ClN2O2
Exact Mass: 362.27
Molecular Weight: 362.98
Elemental Analysis: C, 62.87; H, 10.83; Cl, 9.77; N, 7.72; O, 8.82
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: A 70450; A-70450; A70450
IUPAC/Chemical Name: Cyclohexanehexanamide, delta-amino-N-butyl-gamma-hydroxy-alpha-(1-methylethyl)-, monohydrochloride, (alphaR-(alphaR*,gammaS*,deltaS*))-
InChi Key: OSCAGQDAAPBGKK-PWGAQZMISA-N
InChi Code: InChI=1S/C19H38N2O2.ClH/c1-4-5-11-21-19(23)16(14(2)3)13-18(22)17(20)12-15-9-7-6-8-10-15;/h14-18,22H,4-13,20H2,1-3H3,(H,21,23);1H/t16-,17+,18+;/m1./s1
SMILES Code: O=C(NCCCC)[C@@H](C(C)C)C[C@H](O)[C@@H](N)CC1CCCCC1.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 362.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Stewart K, Abad-Zapatero C. Candida proteases and their inhibition: prospects for antifungal therapy. Curr Med Chem. 2001 Jul;8(8):941-8. Review. PubMed PMID: 11375761.
2: Pranav Kumar SK, Kulkarni VM. Insights into the selective inhibition of Candida albicans secreted aspartyl protease: a docking analysis study. Bioorg Med Chem. 2002 Apr;10(4):1153-70. PubMed PMID: 11836127.
3: Cutfield SM, Dodson EJ, Anderson BF, Moody PC, Marshall CJ, Sullivan PA, Cutfield JF. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure. 1995 Nov 15;3(11):1261-71. PubMed PMID: 8591036.
4: Abad-Zapatero C, Goldman R, Muchmore SW, Hutchins C, Oie T, Stewart K, Cutfield SM, Cutfield JF, Foundling SI, Ray TL. Structure of secreted aspartic proteinases from Candida. Implications for the design of antifungal agents. Adv Exp Med Biol. 1998;436:297-313. Review. PubMed PMID: 9561233.
5: Lerner CG, Goldman RC. Stimuli that induce production of Candida albicans extracellular aspartyl proteinase. J Gen Microbiol. 1993 Jul;139(7):1643-51. PubMed PMID: 7690395.
6: Cutfield S, Marshall C, Moody P, Sullivan P, Cutfield J. Crystallization of inhibited aspartic proteinase from Candida albicans. J Mol Biol. 1993 Dec 20;234(4):1266-9. PubMed PMID: 8263928.